Critical Role for FoxO3a-Dependent Regulation of p21CIP1/WAF1 in Response to Statin Signaling in Cardiac Myocytes

Statins are widely used clinical drugs that exert beneficial growth-suppressive effects in patients with cardiac hypertrophy. We investigated the role of the cell cycle inhibitor p21CIP1/WAF1 (p21) in statin-dependent inhibition of hypertrophic growth in postmitotic cardiomyocytes. We demonstrate that lovastatin fails to inhibit cardiac hypertrophy to angiotensin II in p21−/− mice and that reconstitution of p21 function by TAT.p21 protein transduction can rescue statin action in these otherwise normally developed animals. Lovastatin specifically recruits the forkhead box FoxO3a transcription factor to the p21 promoter, mediating transcriptional transactivation of the p21 gene as analyzed in isolated primary cardiomyocytes. Lovastatin also stimulates protein kinase B/Akt kinase activity, and Akt-dependent phosphorylation forces p21 in the cytoplasm, where it inhibits Rho-kinases contributing to the suppression of cardiomyocyte hypertrophy. Loss of p21 or FoxO3a by RNA interference causes a general inhibition of lovastatin signal transduction. These results suggest that p21 functions as FoxO3a downstream target to mediate an statin-derived anti-hypertrophic response. Taken together, our genetic and biochemical data delineate an essential function of p21 for statin-dependent inhibition of cardiac myocyte hypertrophy.

[1]  Anthony J. Muslin,et al.  Akt1 Is Required for Physiological Cardiac Growth , 2006, Circulation.

[2]  Michael D. Schneider,et al.  Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  J. Liao,et al.  Physiological role of ROCKs in the cardiovascular system. , 2006, American journal of physiology. Cell physiology.

[4]  T. Hewett,et al.  GDF15/MIC-1 Functions As a Protective and Antihypertrophic Factor Released From the Myocardium in Association With SMAD Protein Activation , 2006, Circulation research.

[5]  Steven P Jones,et al.  The ubiquitous role of nitric oxide in cardioprotection. , 2006, Journal of molecular and cellular cardiology.

[6]  S. Houser,et al.  Nuclear Targeting of Akt Enhances Ventricular Function and Myocyte Contractility , 2005, Circulation research.

[7]  J. Liao,et al.  Rho GTPases, statins, and nitric oxide. , 2005, Circulation research.

[8]  J. Massagué,et al.  Smad transcription factors. , 2005, Genes & development.

[9]  R. Colavitti,et al.  This Review Is Part of a Thematic Series on New Paradigms of Transcriptional Control of Myocardial and Vascular Growth, Which Includes the following Articles: Redox-dependent Transcriptional Regulation Excitation-transcription Coupling Redox-dependent Transcriptional Regulation Review Mammalian Redo , 2022 .

[10]  N. Xu,et al.  Targeted Disruption of Smad4 in Cardiomyocytes Results in Cardiac Hypertrophy and Heart Failure , 2005, Circulation research.

[11]  A. Goldberg,et al.  The FOXO3a Transcription Factor Regulates Cardiac Myocyte Size Downstream of AKT Signaling* , 2005, Journal of Biological Chemistry.

[12]  R. Liao.  Yin and Yang of Myocardial Transforming Growth Factor-&bgr;1: Timing Is Everything , 2005, Circulation.

[13]  G. Prendergast,et al.  Modulation of Statin-Activated Shedding of Alzheimer APP Ectodomain by ROCK , 2005, PLoS medicine.

[14]  R. Liao.  Yin and Yang of myocardial transforming growth factor-beta1: timing is everything. , 2005, Circulation.

[15]  H. Schunkert,et al.  Increased Myocardial Collagen Content in Transgenic Rats Overexpressing Cardiac Angiotensin-Converting Enzyme Is Related to Enhanced Breakdown of N-Acetyl-Ser-Asp-Lys-Pro and Increased Phosphorylation of Smad2/3 , 2004, Circulation.

[16]  H. Drexler,et al.  Statin-Induced Improvement of Endothelial Progenitor Cell Mobilization, Myocardial Neovascularization, Left Ventricular Function, and Survival After Experimental Myocardial Infarction Requires Endothelial Nitric Oxide Synthase , 2004, Circulation.

[17]  A. Takeshita,et al.  Long-Term Inhibition of Rho-Kinase Suppresses Left Ventricular Remodeling After Myocardial Infarction in Mice , 2004, Circulation.

[18]  S. Anderson,et al.  Integration of Smad and Forkhead Pathways in the Control of Neuroepithelial and Glioblastoma Cell Proliferation , 2004, Cell.

[19]  Steven F Dowdy,et al.  Cip/Kip proteins: more than just CDKs inhibitors. , 2004, Genes & development.

[20]  Steven P. Gygi,et al.  Stress-Dependent Regulation of FOXO Transcription Factors by the SIRT1 Deacetylase , 2004, Science.

[21]  G. Fonarow,et al.  Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. , 2003, Journal of the American College of Cardiology.

[22]  Steven P Jones,et al.  Simvastatin Attenuates Oxidant-Induced Mitochondrial Dysfunction in Cardiac Myocytes , 2003, Circulation research.

[23]  A. Takeshita,et al.  Long-Term Inhibition of Rho-Kinase Suppresses Angiotensin II–Induced Cardiovascular Hypertrophy in Rats In Vivo: Effect on Endothelial NAD(P)H Oxidase System , 2003, Circulation research.

[24]  M. Hori,et al.  Short-Term Statin Therapy Improves Cardiac Function and Symptoms in Patients With Idiopathic Dilated Cardiomyopathy , 2003, Circulation.

[25]  K. Kaibuchi,et al.  Rho GTPase/Rho Kinase Negatively Regulates Endothelial Nitric Oxide Synthase Phosphorylation through the Inhibition of Protein Kinase B/Akt in Human Endothelial Cells , 2002, Molecular and Cellular Biology.

[26]  G. Hansmann,et al.  Inhibition of Hypoxia-Induced Apoptosis by Modulation of Retinoblastoma Protein–Dependent Signaling in Cardiomyocytes , 2002, Circulation research.

[27]  A. Curcio,et al.  Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor Simvastatin Prevents Cardiac Hypertrophy Induced by Pressure Overload and Inhibits p21 ras Activation , 2002, Circulation.

[28]  Geert J. P. L. Kops,et al.  Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress , 2002, Nature.

[29]  S. Nemoto,et al.  Redox Regulation of Forkhead Proteins Through a p66shc-Dependent Signaling Pathway , 2002, Science.

[30]  K. Node,et al.  Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. , 2001, The Journal of clinical investigation.

[31]  J. Liao,et al.  Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[32]  F. Luft,et al.  Amelioration of Angiotensin II–Induced Cardiac Injury by a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor , 2001, Circulation.

[33]  R. Hajjar,et al.  Akt Activation Preserves Cardiac Function and Prevents Injury After Transient Cardiac Ischemia In Vivo , 2001, Circulation.

[34]  S. Dowdy,et al.  TAT-mediated protein transduction into mammalian cells. , 2001, Methods.

[35]  J. Massagué,et al.  TGFβ influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b , 2001, Nature Cell Biology.

[36]  M. Hung,et al.  Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells , 2001, Nature Cell Biology.

[37]  Myles Brown,et al.  Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription , 2000, Cell.

[38]  U. Laufs,et al.  Targeting Rho in cardiovascular disease. , 2000, Circulation research.

[39]  I. Shiojima,et al.  The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. , 2000, Nature Medicine.

[40]  T. Nakazawa,et al.  Identification of the differential distribution patterns of mRNAs and consensus binding sequences for mouse DAF-16 homologues. , 2000, The Biochemical journal.

[41]  A. Clerk,et al.  Small guanine nucleotide-binding proteins and myocardial hypertrophy. , 2000, Circulation research.

[42]  R. Kitsis,et al.  Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. , 2000, Circulation.

[43]  M. Linton,et al.  Current perspectives on statins. , 2000, Circulation.

[44]  S. Schwarze,et al.  In vivo protein transduction: delivery of a biologically active protein into the mouse. , 1999, Science.

[45]  J Ross,et al.  Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure. , 1999, The Journal of clinical investigation.

[46]  M. Greenberg,et al.  Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor , 1999, Cell.

[47]  P. Vogt,et al.  The akt kinase: molecular determinants of oncogenicity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Natalie A. Lissy,et al.  Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration , 1998, Nature Medicine.

[49]  J. Ross,et al.  Distinct molecular phenotypes in murine cardiac muscle development, growth, and hypertrophy. , 1998, Journal of molecular and cellular cardiology.

[50]  U. Laufs,et al.  Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. , 1998, Circulation.

[51]  Stephen J. Elledge,et al.  Mice Lacking p21 CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control , 1995, Cell.

[52]  K. Kinzler,et al.  Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. , 1995, Cancer research.

[53]  A. M. Lefer,et al.  Mediation of cardioprotection by transforming growth factor-beta. , 1990, Science.

[54]  Robert Walgate,et al.  Proliferation , 1985, Nature.